Alterity Therapeutics (PRNAD) Cash & Equivalents (2009 - 2025)

Alterity Therapeutics (PRNAD) has reported Cash & Equivalents for 16 consecutive years, with $32.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 988.88% year-over-year to $32.3 million; the TTM figure through Dec 2025 stood at $32.3 million (up 988.88% YoY), while the FY2025 annual figure was $21.2 million, up 154.95% from the prior year.
• Cash & Equivalents came in at $32.3 million for Q4 2025 at Alterity Therapeutics, up from $21.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $32.3 million in Q4 2025, with the low at $126388.8 in Q2 2024.
• Average Cash & Equivalents over 5 years is $15.5 million, with a median of $20.9 million recorded in 2021.
• Across the five-year window, Cash & Equivalents sank 99.37% in 2023 and surged 16702.03% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $20.5 million in 2021, then grew by 11.65% to $22.9 million in 2022, then plunged by 64.93% to $8.0 million in 2023, then slumped by 63.01% to $3.0 million in 2024, then jumped by 988.88% to $32.3 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $32.3 million, $21.2 million, and $3.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.